Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Regulus Therapeutics Inc shares valued at $7,280 were purchased by Collier Kathryn J on Jul 25 ’24. At $1.82 per share, Collier Kathryn J acquired 4,000 shares. The insider’s holdings grew to 6,740 shares worth approximately $11053.599999999999 following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, CALSADA CRISPINA sold 5,468 shares, netting a total of over 6,510 in proceeds. Following the sale of shares at $1.19 each, the insider now holds 5,782 shares.
Before that, Aker Christopher Ray had sold 5,468 shares from its account. In a trade valued at $6,510, the Sr. VP & General Counsel traded Regulus Therapeutics Inc shares for $1.19 each. Upon closing the transaction, the insider’s holdings decreased to 5,468 shares, worth approximately $16491.84.
As published in their initiating research note from Oppenheimer on August 02, 2024, Regulus Therapeutics Inc [RGLS] has been an Outperform and the price target has been revised to $7. Analysts at Leerink Partners started covering the stock with ‘”an Outperform”‘ outlook in a report released in mid March. As of March 28, 2018, B. Riley FBR Inc. has initiated its “Neutral” rating for RGLS. Earlier on January 05, 2018, Leerink Partners initiated its rating. Their recommendation was “an Outperform” for RGLS stock.
Analyzing RGLS Stock Performance
During the last five days, there has been a surge of approximately 17.14%. Over the course of the year, Regulus Therapeutics Inc shares have jumped approximately 28.13%. Shares of the company reached a 52-week high of $3.7900 on 03/12/24 and a 52-week low of $1.0800 on 01/17/24. A 50-day SMA is recorded $1.5299, while a 200-day SMA reached $1.8778. Nevertheless, trading volume fell to 0.32 million shares from 0.26 million shares the previous day.
Support And Resistance Levels for Regulus Therapeutics Inc (RGLS)
According to the 24-hour chart, there is a support level at 1.5550, which, if violated, would cause prices to drop to 1.4700. In the upper region, resistance lies at 1.6900. The next price resistance is at 1.7400. RSI (Relative Strength Index) is 62.17 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.0869, which suggests the price will decrease in the coming days. Percent R is at 4.23%, indicating bullish price movement. Stochastics %K at holding indicates that the stock is to be held.
